Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $148.9412.

A number of research firms recently commented on ILMN. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Barclays increased their price target on Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a report on Wednesday, June 24th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Finally, Canaccord Genuity Group cut their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st.

Illumina Price Performance

NASDAQ:ILMN opened at $188.68 on Monday. Illumina has a 12-month low of $88.00 and a 12-month high of $189.46. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $28.55 billion, a P/E ratio of 34.31, a P/E/G ratio of 3.53 and a beta of 1.47. The stock’s fifty day simple moving average is $154.74 and its 200-day simple moving average is $139.42.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts expect that Illumina will post 5.21 earnings per share for the current year.

Insider Activity at Illumina

In other news, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently made changes to their positions in ILMN. Empowered Funds LLC grew its stake in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in Illumina during the second quarter worth approximately $275,000. Marshall Wace LLP increased its stake in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC increased its stake in Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares during the period. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.